Username


Password

Preview

José Ramos

Publications

  • TOP 3
  • Eva de Lago; Miguel Moreno-Martet; Ana Cabranes; José A Ramos; Javier Fernández-Ruiz
    Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
  • Onintza Sagredo; M Ruth Pazos; Valentina Satta; José A Ramos; Roger G Pertwee; Javier Fernández-Ruiz
    Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.
  • Javier Fernández-Ruiz; Miguel Moreno-Martet; Carmen Rodríguez-Cueto; Cristina Palomo-Garo; María Gómez-Cañas; Sara Valdeolivas; Carmen Guaza; Julián Romero; Manuel Guzmán; Raphael Mechoulam; et al.
    Prospects for cannabinoid therapies in basal ganglia disorders.
Register to see all publications

Register for free to view:

Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the research activity
of experts around the globe
Register to see more

Geonetwork of José Ramos (preview)

  • Cities where this author has publications
  • Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

  • 2012: Eva de Lago; Miguel Moreno-Martet; Ana Cabranes; José A Ramos; Javier Fernández-Ruiz
    Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
    Neuropharmacology 2012;62(7):2299-308.
  • 2011: Onintza Sagredo; M Ruth Pazos; Valentina Satta; José A Ramos; Roger G Pertwee; Javier Fernández-Ruiz
    Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.
    Journal of neuroscience research 2011;89(9):1509-18.
  • 2011: Javier Fernández-Ruiz; Miguel Moreno-Martet; Carmen Rodríguez-Cueto; Cristina Palomo-Garo; María Gómez-Cañas; Sara Valdeolivas; Carmen Guaza; Julián Romero; Manuel Guzmán; Raphael Mechoulam; et al.
    Prospects for cannabinoid therapies in basal ganglia disorders.
    British journal of pharmacology 2011;163(7):1365-78.
  • 2010: Javier Fernández-Ruiz; Mariluz Hernández; José A Ramos
    Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders.
    CNS neuroscience & therapeutics 2010;16(3):e72-91.
  • 2009: Francisco Arias; Israel Ampuero; Onintza Sagredo; Francisca Almódovar; Sergio Sánchez; Juan Jose Gorgojo; Jose Antonio Ramos
    Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study.
    Psychiatric genetics 2009;19(6):336.
  • 2009: Marina Rubio; Rosario de Miguel; Javier Fernández-Ruiz; Dolores Gutiérrez-López; Mauro A M Carai; José A Ramos
    Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas.
    Drug and alcohol dependence 2009;99(1-3):354-8.
  • 2008: Marina Rubio; Javier Fernández-Ruiz; Rosario de Miguel; Begoña Maestro; J Michael Walker; José A Ramos
    CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats.
    Neuropharmacology 2008;54(6):976-88.
  • 2008: Javier Fernández-Ruiz; María Ruth Pazos; Moisés García-Arencibia; Onintza Sagredo; José A Ramos
    Role of CB2 receptors in neuroprotective effects of cannabinoids.
    Molecular and cellular endocrinology 2008;286(1-2 Suppl 1):S91-6.
  • 2007: María Gómez-Ruiz; Mariluz Hernández; Rosario de Miguel; Jose A Ramos
    An overview on the biochemistry of the cannabinoid system.
    Molecular neurobiology 2007;36(1):3-14.
  • 2007: Javier Fernández-Ruiz; Manuel Guzmán; José A Ramos
    Preface: cannabinoids as new tools for the treatment of neurological disorders.
    Molecular neurobiology 2007;36(1):1-2.
  • 2007: Onintza Sagredo; José A Ramos; Alessandra Decio; Raphael Mechoulam; Javier Fernández-Ruiz
    Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.
    The European journal of neuroscience 2007;26(4):843-51.
  • 2007: Moisés García-Arencibia; Sara González; Eva de Lago; José A Ramos; Raphael Mechoulam; Javier Fernández-Ruiz
    Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
    Brain research 2007;1134(1):162-70.
  • 2007: Eva de Lago; Silvia Ortega-Gutiérrez; José A Ramos; Maria L López Rodríguez; Javier Fernández-Ruiz
    Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions.
    Life sciences 2007;80(10):979-88.
  • 2007: Javier Fernández-Ruiz; Julián Romero; Guillermo Velasco; Rosa M Tolón; José A Ramos; Manuel Guzmán
    Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
    Trends in pharmacological sciences 2007;28(1):39-45.
  • 2006: Sara González; Camila Scorticati; Moisés García-Arencibia; Rosario de Miguel; José A Ramos; Javier Fernández-Ruiz
    Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
    Brain research 2006;1073-1074():209-19.
  • 2006: Onintza Sagredo; José A Ramos; Javier Fernández-Ruiz; María L López Rodríguez; Rosario de Miguel
    Chronic Delta9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex.
    Naunyn-Schmiedeberg's archives of pharmacology 2006;372(4):313-7.
  • 2006: Eva de Lago; Javier Fernández-Ruiz; Silvia Ortega-Gutiérrez; Ana Cabranes; Gareth Pryce; David Baker; Mariluz López-Rodríguez; José Antonio Ramos
    UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2006;16(1):7-18.
  • 2005: Ana Cabranes; Katerina Venderova; Eva de Lago; Filomena Fezza; Antonio Sánchez; Leyre Mestre; Marta Valenti; Antonio García-Merino; José Antonio Ramos; Vincenzo Di Marzo; et al.
    Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Neurobiology of disease 2005;20(2):207-17.
  • 2005: Eva de Lago; Paolo Urbani; José Antonio Ramos; Vincenzo Di Marzo; Javier Fernández-Ruiz
    Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.
    Brain research 2005;1050(1-2):210-6.
  • 2005: José Antonio Ramos; Sara González; Onintza Sagredo; María Gómez-Ruiz; Javier Fernández-Ruiz
    Therapeutic potential of the endocannabinoid system in the brain.
    Mini reviews in medicinal chemistry 2005;5(7):609-17.
  • 2005: Sara González; María Angeles Mena; Isabel Lastres-Becker; Alba Serrano; Justo G de Yébenes; José A Ramos; Javier Fernández-Ruiz
    Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice.
    Brain research 2005;1046(1-2):195-206.
  • 2005: Isabel Lastres-Becker; Francisco Molina-Holgado; José A Ramos; Raphael Mechoulam; Javier Fernández-Ruiz
    Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
    Neurobiology of disease 2005;19(1-2):96-107.
  • 2005: J A Ramos; M Gómez; R de Miguel
    Effects on development.
    Handbook of experimental pharmacology 2005;(168):643-56.
  • 2004: Sara González; Marta Valenti; Rosario de Miguel; Filomena Fezza; Javier Fernández-Ruiz; Vincenzo Di Marzo; José A Ramos
    Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse.
    British journal of pharmacology 2004;143(4):455-64.
  • 2004: Sara González; Javier Fernández-Ruiz; Vincenzo Di Marzo; Mariluz Hernández; Cristina Arévalo; Cristina Nicanor; Maria Grazia Cascio; Emilio Ambrosio; José A Ramos
    Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
    Drug and alcohol dependence 2004;74(2):159-70.
  • 2004: Eva de Lago; Rosario de Miguel; Isabel Lastres-Becker; José A Ramos; Javier Fernández-Ruiz
    Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence.
    Brain research 2004;1007(1-2):152-9.
  • 2004: María L López-Rodríguez; David Ayala; Alma Viso; Bellinda Benhamú; Roberto Fernández de La Pradilla; Fernando Zarza; José A Ramos
    Synthesis and structure-activity relationships of a new model of arylpiperazines. Part 7: Study of the influence of lipophilic factors at the terminal amide fragment on 5-HT(1A) affinity/selectivity.
    Bioorganic & medicinal chemistry 2004;12(6):1551-7.
  • 2004: Lidia Ruiz-Llorente; Silvia Ortega-Gutiérrez; Alma Viso; María G Sánchez; Ana M Sánchez; Carlos Fernández; José A Ramos; Cecilia Hillard; Miguel A Lasunción; María L López-Rodríguez; et al.
    Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study.
    British journal of pharmacology 2004;141(3):457-67.
  • 2004: Javier Fernández-Ruiz; María Gómez; Mariluz Hernández; Rosario de Miguel; José A Ramos
    Cannabinoids and gene expression during brain development.
    Neurotoxicity research 2004;6(5):389-401.
  • 2004: I Suárez; G Bodega; M Rubio; J J Fernández-Ruiz; J A Ramos; B Fernández
    Prenatal cannabinoid exposure down- regulates glutamate transporter expressions (GLAST and EAAC1) in the rat cerebellum.
    Developmental neuroscience 2004;26(1):45-53.
  • 2004: Isabel Suárez; Guillermo Bodega; Javier Fernández-Ruiz; José Antonio Ramos; Miguel Rubio; Benjamín Fernández
    Down-regulation of the AMPA glutamate receptor subunits GluR1 and GluR2/3 in the rat cerebellum following pre- and perinatal delta9-tetrahydrocannabinol exposure.
    Cerebellum (London, England) 2004;3(2):66-74.
  • 2003: María Gómez; Mariluz Hernández; Björn Johansson; Rosario de Miguel; José Antonio Ramos; Javier Fernández-Ruiz
    Prenatal cannabinoid and gene expression for neural adhesion molecule L1 in the fetal rat brain.
    Brain research. Developmental brain research 2003;147(1-2):201-7.
  • 2003: María L López-Rodríguez; Esther Porras; M José Morcillo; Bellinda Benhamú; Luis J Soto; José L Lavandera; José A Ramos; Mireia Olivella; Mercedes Campillo; Leonardo Pardo
    Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.
    Journal of medicinal chemistry 2003;46(26):5638-50.
  • 2003: Christopher J Fowler; Gunnar Tiger; María L López-Rodríguez; Alma Viso; Silvia Ortega-Gutiérrez; José A Ramos
    Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin.
    Journal of enzyme inhibition and medicinal chemistry 2003;18(3):225-31.
  • 2003: Begoña González; Rosario de Miguel; Sonsoles Martín; Alberto Pérez-Rosado; Julián Romero; Carmen García-Lecumberri; Javier Fernández-Ruiz; José Antonio Ramos; Emilio Ambrosio
    Effects of perinatal exposure to delta 9-tetrahydrocannabinol on operant morphine-reinforced behavior.
    Pharmacology, biochemistry, and behavior 2003;75(3):577-84.
  • 2003: Sara González; Patricia C Schmid; Javier Fernández-Ruiz; Randy Krebsbach; Harald H O Schmid; José A Ramos
    Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats.
    Addiction biology 2003;8(2):159-66.
  • 2003: María L López-Rodríguez; Alma Viso; Silvia Ortega-Gutiérrez; Christopher J Fowler; Gunnar Tiger; Eva de Lago; Javier Fernández-Ruiz; José A Ramos
    Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase.
    Journal of medicinal chemistry 2003;46(8):1512-22.
  • 2003: María L López-Rodríguez; Alma Viso; Silvia Ortega-Gutiérrez; Christopher J Fowler; Gunnar Tiger; Eva de Lago; Javier Fernández-Ruiz; José A Ramos
    Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors.
    European journal of medicinal chemistry 2003;38(4):403-12.
  • 2002: Sara González; Maria Grazia Cascio; Javier Fernández-Ruiz; Filomena Fezza; Vincenzo Di Marzo; José A Ramos
    Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine.
    Brain research 2002;954(1):73-81.
  • 2002: Eva de Lago; Javier Fernández-Ruiz; Silvia Ortega-Gutiérrez; Alma Viso; María Luz López-Rodríguez; José A Ramos
    UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide.
    European journal of pharmacology 2002;449(1-2):99-103.
  • 2002: Julián Romero; Isabel Lastres-Becker; Rosario de Miguel; Fernando Berrendero; José A Ramos; Javier Fernández-Ruiz
    The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects.
    Pharmacology & therapeutics 2002;95(2):137-52.
  • 2002: Henrik H Hansen; Iñigo Azcoitia; Sebastián Pons; Julián Romero; Luis Miguel García-Segura; José Antonio Ramos; Harald S Hansen; Javier Fernández-Ruiz
    Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity.
    Journal of neurochemistry 2002;82(1):154-8.
  • 2002: Eva M Romero; Beatriz Fernández; Onintza Sagredo; Nuria Gomez; Leyre Urigüen; Carmen Guaza; Rosario De Miguel; Jose Antonio Ramos; M Paz Viveros
    Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats.
    Brain research. Developmental brain research 2002;136(2):85-92.
  • 2002: Isabel Lastres-Becker; Henrik H Hansen; Fernando Berrendero; Rosario De Miguel; Alberto Pérez-Rosado; Jorge Manzanares; José A Ramos; Javier Fernández-Ruiz
    Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Synapse (New York, N.Y.) 2002;44(1):23-35.
  • 2002: I Lastres-Becker; F Berrendero; J J Lucas; E Martín-Aparicio; A Yamamoto; J A Ramos; J J Fernández-Ruiz
    Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.
    Brain research 2002;929(2):236-42.
  • 2002: Sara Gonzalez; Javier Fernandez-Ruiz; Valentina Sparpaglione; Daniela Parolaro; Jose A Ramos
    Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels.
    Drug and alcohol dependence 2002;66(1):77-84.
  • 2002: J Fernández-Ruiz; I Lastres-Becker; A Cabranes; S González; J A Ramos
    Endocannabinoids and basal ganglia functionality.
    Prostaglandins, leukotrienes, and essential fatty acids 2002;66(2-3):257-67.
  • 2002: I Suárez; G Bodega; J J Fernández-Ruiz; J A Ramos; M Rubio; B Fernández
    Reduced glial fibrillary acidic protein and glutamine synthetase expression in astrocytes and Bergmann glial cells in the rat cerebellum caused by delta(9)-tetrahydrocannabinol administration during development.
    Developmental neuroscience 2002;24(4):300-12.
  • 2001: M L López-Rodríguez; A Viso; S Ortega-Gutiérrez; I Lastres-Becker; S González; J Fernández-Ruiz; J A Ramos
    Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.
    Journal of medicinal chemistry 2001;44(26):4505-8.
  • 2001: I Lastres-Becker; M Cebeira; M L de Ceballos; B Y Zeng; P Jenner; J A Ramos; J J Fernández-Ruiz
    Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.
    The European journal of neuroscience 2001;14(11):1827-32.
  • 2001: F Berrendero; A Sánchez; A Cabranes; C Puerta; J A Ramos; A García-Merino; J Fernández-Ruiz
    Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis.
    Synapse (New York, N.Y.) 2001;41(3):195-202.
  • 2001: I Lastres-Becker; F Fezza; M Cebeira; T Bisogno; J A Ramos; A Milone; J Fernández-Ruiz; V Di Marzo
    Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.
    Neuroreport 2001;12(10):2125-9.
  • 2000: S González; G Mauriello-Romanazzi; F Berrendero; J A Ramos; M F Franzoni; J Fernández-Ruiz
    Decreased cannabinoid CB1 receptor mRNA levels and immunoreactivity in pituitary hyperplasia induced by prolonged exposure to estrogens.
    Pituitary 2000;3(4):221-6.
  • 2000: M L López-Rodríguez; E Porras; B Benhamú; J A Ramos; M J Morcillo; J L Lavandera
    First pharmacophoric hypothesis for 5-HT7 antagonism.
    Bioorganic & medicinal chemistry letters 2000;10(10):1097-100.
  • 2000: S González; T Bisogno; T Wenger; J Manzanares; A Milone; F Berrendero; V Di Marzo; J A Ramos; J J Fernández-Ruiz
    Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland.
    Biochemical and biophysical research communications 2000;270(1):260-6.
  • 2000: V Di Marzo; F Berrendero; T Bisogno; S González; P Cavaliere; J Romero; M Cebeira; J A Ramos; J J Fernández-Ruiz
    Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats.
    Journal of neurochemistry 2000;74(4):1627-35.
  • 2000: A Pérez-Rosado; J Manzanares; J Fernández-Ruiz; J A Ramos
    Prenatal Delta(9)-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences.
    Brain research. Developmental brain research 2000;120(1):77-81.
  • 2000: M Hernández; F Berrendero; I Suárez; L García-Gil; M Cebeira; K Mackie; J A Ramos; J Fernández-Ruiz
    Cannabinoid CB(1) receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme.
    Brain research 2000;857(1-2):56-65.
  • 2000: I Suárez; G Bodega; J A Ramos; J J Fernández-Ruiz; B Fernández
    Neuronal and astroglial response to pre- and perinatal exposure to delta-9-tetra- hydrocannabinol in the rat substantia nigra.
    Developmental neuroscience 2000;22(4):253-63.
  • 2000: J Romero; F Berrendero; A Pérez-Rosado; J Manzanares; A Rojo; J J Fernández-Ruiz; J G de Yebenes; J A Ramos
    Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen.
    Life sciences 2000;66(6):485-94.
  • 2000: J Fernández-Ruiz; F Berrendero; M L Hernández; J A Ramos
    The endogenous cannabinoid system and brain development.
    Trends in neurosciences 2000;23(1):14-20.
  • 1999: T Wenger; J J Fernández-Ruiz; J A Ramos
    Immunocytochemical demonstration of CB1 cannabinoid receptors in the anterior lobe of the pituitary gland.
    Journal of neuroendocrinology 1999;11(11):873-8.
  • 1999: F Berrendero; N Sepe; J A Ramos; V Di Marzo; J J Fernández-Ruiz
    Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period.
    Synapse (New York, N.Y.) 1999;33(3):181-91.
  • 1999: S González; J Manzanares; F Berrendero; T Wenger; J Corchero; T Bisogno; J Romero; J A Fuentes; V Di Marzo; J A Ramos; et al.
    Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland.
    Neuroendocrinology 1999;70(2):137-45.
  • 1999: J Romero; F Berrendero; L García-Gil; S Y Lin; A Makriyannis; J A Ramos; J J Fernández-Ruiz
    Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPgammaS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide.
    Neurochemistry international 1999;34(6):473-82.
  • 1999: L García-Gil; J Romero; J A Ramos; J J Fernández-Ruiz
    Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol.
    Drug and alcohol dependence 1999;55(1-2):127-36.
  • 1999: L Garcia-Gil; R de Miguel; J Romero; A Perez; J A Ramos; J J Fernández-Ruiz
    Perinatal delta9-tetrahydrocannabinol exposure augmented the magnitude of motor inhibition caused by GABA(B), but not GABA(A), receptor agonists in adult rats.
    Neurotoxicology and teratology 1999;21(3):277-83.
  • 1999: J Corchero; J Romero; F Berrendero; J Fernandez-Ruiz; J A Ramos; J A Fuentes; J Manzanares
    Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen.
    Brain research. Molecular brain research 1999;67(1):148-57.
  • 1999: T Bisogno; F Berrendero; G Ambrosino; M Cebeira; J A Ramos; J J Fernandez-Ruiz; V Di Marzo
    Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function.
    Biochemical and biophysical research communications 1999;256(2):377-80.
  • 1999: J J Fernández-Ruiz; F Berrendero; M L Hernández; J Romero; J A Ramos
    Role of endocannabinoids in brain development.
    Life sciences 1999;65(6-7):725-36.
  • 1999: S González; J Romero; R de Miguel; I Lastres-Becker; M A Villanua; A Makriyannis; J A Ramos; J J Fernández-Ruiz
    Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide.
    Life sciences 1999;65(3):327-36.
  • 1998: R de Miguel; J Romero; R M Muñoz; L García-Gil; S González; M A Villanua; A Makriyannis; J A Ramos; J J Fernández-Ruiz
    Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs.
    Biochemical pharmacology 1998;56(10):1331-8.
  • 1998: J Romero; F Berrendero; J Manzanares; A Pérez; J Corchero; J A Fuentes; J J Fernández-Ruiz; J A Ramos
    Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol.
    Synapse (New York, N.Y.) 1998;30(3):298-308.
  • 1998: G Vela; S Martín; L García-Gil; J A Crespo; M Ruiz-Gayo; J J Fernández-Ruiz; C García-Lecumberri; D Pélaprat; J A Fuentes; J A Ramos; et al.
    Maternal exposure to delta9-tetrahydrocannabinol facilitates morphine self-administration behavior and changes regional binding to central mu opioid receptors in adult offspring female rats.
    Brain research 1998;807(1-2):101-9.
  • 1998: J Romero; F Berrendero; L García-Gil; J A Ramos; J J Fernández-Ruiz
    Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.
    Journal of molecular neuroscience : MN 1998;11(2):109-19.
  • 1998: F Berrendero; J Romero; L García-Gil; I Suarez; P De la Cruz; J A Ramos; J J Fernández-Ruiz
    Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats.
    Biochimica et biophysica acta 1998;1407(3):205-14.
  • 1998: L García-Gil; J A Ramos; T Rubino; D Parolaro; J J Fernández-Ruiz
    Perinatal delta9-tetrahydrocannabinol exposure did not alter dopamine transporter and tyrosine hydroxylase mRNA levels in midbrain dopaminergic neurons of adult male and female rats.
    Neurotoxicology and teratology 1998;20(5):549-53.
  • 1998: F Berrendero; L García-Gil; M L Hernández; J Romero; M Cebeira; R de Miguel; J A Ramos; J J Fernández-Ruiz
    Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development.
    Development (Cambridge, England) 1998;125(16):3179-88.
  • 1998: J Romero; F Berrendero; L Garcia-Gil; P de la Cruz; J A Ramos; J J Fernández-Ruiz
    Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5'O-(thio)-triphosphate binding in the basal ganglia of aged rats.
    Neuroscience 1998;84(4):1075-83.
  • 1998: J Romero; J J Fernández-Ruiz; G Vela; M Ruiz-Gayo; J A Fuentes; J A Ramos
    Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice.
    Drug and alcohol dependence 1998;50(3):241-9.
  • 1998: J Manzanares; J Corchero; J Romero; J J Fernandez-Ruiz; J A Ramos; J A Fuentes
    Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain.
    Brain research. Molecular brain research 1998;55(1):126-32.
  • 1998: J Corchero; L García-Gil; J Manzanares; J J Fernández-Ruiz; J A Fuentes; J A Ramos
    Perinatal delta9-tetrahydrocannabinol exposure reduces proenkephalin gene expression in the caudate-putamen of adult female rats.
    Life sciences 1998;63(10):843-50.
  • 1998: J Romero; T Wenger; R de Miguel; J A Ramos; J J Fernández-Ruiz
    Cannabinoid receptor binding did not vary in several hypothalamic nuclei after hypothalamic deafferentation.
    Life sciences 1998;63(5):351-6.
  • 1998: J Romero; R de Miguel; J A Ramos; J J Fernández-Ruiz
    The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake.
    Life sciences 1998;62(4):351-63.
  • 1997: L García-Gil; R De Miguel; R M Muñoz; M Cebeira; M A Villanua; J A Ramos; J J Fernández-Ruiz
    Perinatal delta(9)-tetrahydrocannabinol exposure alters the responsiveness of hypothalamic dopaminergic neurons to dopamine-acting drugs in adult rats.
    Neurotoxicology and teratology 1997;19(6):477-87.
  • 1997: J Romero; E Garcia-Palomero; F Berrendero; L Garcia-Gil; M L Hernandez; J A Ramos; J J Fernández-Ruiz
    Atypical location of cannabinoid receptors in white matter areas during rat brain development.
    Synapse (New York, N.Y.) 1997;26(3):317-23.
  • 1997: J J Fernández-Ruiz; R M Muñoz; J Romero; M A Villanua; A Makriyannis; J A Ramos
    Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.
    Biochemical pharmacology 1997;53(12):1919-27.
  • 1997: J Romero; E Garcia-Palomero; J G Castro; L Garcia-Gil; J A Ramos; J J Fernandez-Ruiz
    Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.
    Brain research. Molecular brain research 1997;46(1-2):100-8.
  • 1997: M L Hernández; L García-Gil; F Berrendero; J A Ramos; J J Fernández-Ruiz
    delta 9-Tetrahydrocannabinol increases activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons.
    Journal of molecular neuroscience : MN 1997;8(2):83-91.
  • 1996: L García; R de Miguel; J A Ramos; J J Fernàndez-Ruiz
    Perinatal delta 9-tetrahydrocannabinol exposure in rats modifies the responsiveness of midbrain dopaminergic neurons in adulthood to a variety of challenges with dopaminergic drugs.
    Drug and alcohol dependence 1996;42(3):155-66.
  • 1996: M Navarro; R de Miguel; F Rodríguez de Fonseca; J A Ramos; J J Fernández-Ruiz
    Perinatal cannabinoid exposure modifies the sociosexual approach behavior and the mesolimbic dopaminergic activity of adult male rats.
    Behavioural brain research 1996;75(1-2):91-8.
  • 1996: A Bonnin; R de Miguel; J G Castro; J A Ramos; J J Fernandez-Ruiz
    Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain.
    Journal of molecular neuroscience : MN 1996;7(4):291-308.
  • 1996: J Romero; E García-Palomero; S Y Lin; J A Ramos; A Makriyannis; J J Fernández-Ruiz
    Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand.
    Life sciences 1996;58(15):1249-57.
  • 1995: J Romero; R de Miguel; E García-Palomero; J J Fernández-Ruiz; J A Ramos
    Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function.
    Brain research 1995;694(1-2):223-32.
  • 1995: M Guzmán; J J Fernández-Ruiz; C Sánchez; G Velasco; J A Ramos
    Effects of anandamide on hepatic fatty acid metabolism.
    Biochemical pharmacology 1995;50(6):885-8.
  • 1995: J Romero; L García; J J Fernández-Ruiz; M Cebeira; J A Ramos
    Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
    Pharmacology, biochemistry, and behavior 1995;51(4):731-7.
  • 1995: A Bonnin; R de Miguel; M L Hernández; J A Ramos; J J Fernández-Ruiz
    The prenatal exposure to delta 9-tetrahydrocannabinol affects the gene expression and the activity of tyrosine hydroxylase during early brain development.
    Life sciences 1995;56(23-24):2177-84.
  • 1995: J Romero; L García; M Cebeira; D Zadrozny; J J Fernández-Ruiz; J A Ramos
    The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons.
    Life sciences 1995;56(23-24):2033-40.
  • 1994: A Bonnin; R de Miguel; J J Fernández-Ruiz; M Cebeira; J A Ramos
    Possible role of the cytochrome P450-linked monooxygenase system in preventing delta 9-tetrahydrocannabinol-induced stimulation of tuberoinfundibular dopaminergic activity in female rats.
    Biochemical pharmacology 1994;48(7):1387-92.
  • 1994: A Bonnin; R de Miguel; J C Rodríguez-Manzaneque; J J Fernández-Ruiz; A Santos; J A Ramos
    Changes in tyrosine hydroxylase gene expression in mesencephalic catecholaminergic neurons of immature and adult male rats perinatally exposed to cannabinoids.
    Brain research. Developmental brain research 1994;81(1):147-50.
  • 1994: F Rodríguez de Fonseca; M Cebeira; J A Ramos; M Martín; J J Fernández-Ruiz
    Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement.
    Life sciences 1994;54(3):159-70.
  • 1994: F Rodríguez de Fonseca; M A Gorriti; J J Fernández-Ruiz; T Palomo; J A Ramos
    Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment.
    Pharmacology, biochemistry, and behavior 1994;47(1):33-40.
  • 1994: M Navarro; F Rodríguez de Fonseca; M L Hernández; J A Ramos; J J Fernández-Ruiz
    Motor behavior and nigrostriatal dopaminergic activity in adult rats perinatally exposed to cannabinoids.
    Pharmacology, biochemistry, and behavior 1994;47(1):47-58.
  • 1994: M L Hernández; J J Fernández-Ruiz; M Navarro; R de Miguel; M Cebeira; L Vaticón; J A Ramos
    Modifications of mesolimbic and nigrostriatal dopaminergic activities after intracerebroventricular administration of prolactin.
    Journal of neural transmission. General section 1994;96(1):63-79.
  • 1993: M Navarro; J J Fernández-Ruiz; R de Miguel; M L Hernández; M Cebeira; J A Ramos
    An acute dose of delta 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity.
    Behavioural brain research 1993;57(1):37-46.
  • 1993: A Bonnin; J A Ramos; F Rodríguez de Fonseca; M Cebeira; J J Fernández-Ruiz
    Acute effects of delta 9-tetrahydrocannabinol on tuberoinfundibular dopamine activity, anterior pituitary sensitivity to dopamine and prolactin release vary as a function of estrous cycle.
    Neuroendocrinology 1993;58(3):280-6.
  • 1993: M Navarro; J J Fernández-Ruiz; R De Miguel; M L Hernández; M Cebeira; J A Ramos
    Motor disturbances induced by an acute dose of delta 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations.
    Pharmacology, biochemistry, and behavior 1993;45(2):291-8.
  • 1993: F Rodríguez de Fonseca; J A Ramos; A Bonnin; J J Fernández-Ruiz
    Presence of cannabinoid binding sites in the brain from early postnatal ages.
    Neuroreport 1993;4(2):135-8.
  • 1993: A Bonnin; J J Fernández-Ruiz; M Martín; F Rodríguez de Fonseca; M L Hernández; J A Ramos
    delta 9-Tetrahydrocannabinol affects mesolimbic dopaminergic activity in the female rat brain: interactions with estrogens.
    Journal of neural transmission. General section 1993;92(2-3):81-95.
  • 1992: M Navarro; J J Fernández-Ruiz; F Rodriguez de Fonseca; M L Hernández; M Cebeira; J A Ramos
    Modifications of striatal D2 dopaminergic postsynaptic sensitivity during development of morphine tolerance-dependence in mice.
    Pharmacology, biochemistry, and behavior 1992;43(2):603-8.
  • 1992: A Bonnin; J J Ferández-Ruiz; M Martín; F R De Fonseca; R De Miguel; J A Ramos
    Estrogenic modulation of delta(9)-Tetrahydrocannabinol effects on nigrostriatal dopaminergic activity in the female rat brain.
    Molecular and cellular neurosciences 1992;3(4):315-25.
  • 1992: F Rodríguez De Fonseca; J J Fernández-Ruiz; L L Murphy; M Cebeira; R W Steger; A Bartke; J A Ramos
    Acute effects of delta-9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas.
    Pharmacology, biochemistry, and behavior 1992;42(2):269-75.
  • 1992: J Fernandez-Ruiz; R De Miguel; M L Hernandez; M Cebeira; J A Ramos
    Comparisons between brain dopaminergic neurons of juvenile and aged rats: sex-related differences.
    Mechanisms of ageing and development 1992;63(1):45-55.
  • 1992: F Rodríguez de Fonseca; M L Hernández; R de Miguel; J J Fernández-Ruiz; J A Ramos
    Early changes in the development of dopaminergic neurotransmission after maternal exposure to cannabinoids.
    Pharmacology, biochemistry, and behavior 1992;41(3):469-74.
  • 1991: M L Hernández; R de Miguel; J A Ramos; J J Fernández-Ruiz
    Is prolactin playing a role in the regulation of catecholamine synthesis and release from male rat adrenal medulla?
    Journal of endocrinological investigation 1991;14(3):201-8.
  • 1991: F Rodríguez de Fonseca; M Cebeira; J J Fernández-Ruiz; M Navarro; J A Ramos
    Effects of pre- and perinatal exposure to hashish extracts on the ontogeny of brain dopaminergic neurons.
    Neuroscience 1991;43(2-3):713-23.
  • 1991: J J Fernández-Ruiz; M L Hernández; R de Miguel; J A Ramos
    Nigrostriatal and mesolimbic dopaminergic activities were modified throughout the ovarian cycle of female rats.
    Journal of neural transmission. General section 1991;85(3):223-9.
  • 1991: M L Hernández; J J Fernández-Ruiz; R de Miguel; J A Ramos
    Time-dependent effects of ovarian steroids on tyrosine hydroxylase activity in the limbic forebrain of female rats.
    Journal of neural transmission. General section 1991;83(1-2):77-84.
  • 1991: M Cebeira; M L Hernandez; F Rodriguez de Fonseca; R de Miguel; J J Fernandez-Ruiz; J A Ramos
    Lack of effect of prolactin on the dopaminergic receptor sensitivity in striatal and limbic areas after experimentally-induced alterations in its peripheral levels.
    Life sciences 1991;48(6):531-41.
  • 1990: M L Hernández; R de Miguel; J A Ramos; J J Fernández-Ruiz
    Prolactin inhibits the activity of tyrosine hydroxylase in cultured bovine adrenal chromaffin cells in a dose-dependent manner.
    Brain research 1990;528(1):175-8.
  • 1990: J J Fernández-Ruiz; R de Miguel; M L Hernández; J A Ramos
    Time-course of the effects of ovarian steroids on the activity of limbic and striatal dopaminergic neurons in female rat brain.
    Pharmacology, biochemistry, and behavior 1990;36(3):603-6.
  • 1990: F Rodriguez de Fonseca; M Cebeira; M L Hernández; J A Ramos; J J Fernández-Ruiz
    Changes in brain dopaminergic indices induced by perinatal exposure to cannabinoids in rats.
    Brain research. Developmental brain research 1990;51(2):237-40.
  • 1989: J J Fernandez-Ruiz; A R Bukhari; M L Hernandez; J Alemany; J A Ramos
    Sex- and age-related changes in catecholamine metabolism and release of rat adrenal gland.
    Neurobiology of aging 1989;10(4):331-5.
  • 1989: J J Fernández-Ruiz; J C Amor; J A Ramos
    Time-dependent effects of estradiol and progesterone on the number of striatal dopaminergic D2-receptors.
    Brain research 1989;476(2):388-95.
  • 1989: R de Miguel; J J Fernández-Ruiz; M L Hernández; J A Ramos
    Role of ovarian steroids on the catecholamine synthesis and release in female rat adrenal: in vivo and in vitro studies.
    Life sciences 1989;44(25):1979-86.
  • 1989: J J Fernández-Ruiz; C Alvarez-Sanz; J A Ramos
    2-Hydroxyestradiol is not mediating the effects of estradiol on tuberoinfundibular dopaminergic neurons controlling prolactin secretion in female rats.
    Journal of steroid biochemistry 1989;32(1A):71-5.
  • 1988: J J Fernandez-Ruiz; R Martinez-Arrieta; M L Hernandez; J A Ramos
    Possible direct effect of prolactin on catecholamine synthesis and release in rat adrenal medulla: in vitro studies.
    Journal of endocrinological investigation 1988;11(8):603-8.
  • 1988: J J Fernández-Ruiz; C Agrasal; M Cebeira; J A Tresguerres; A I Esquifino; J A Ramos
    Effects of estradiol on circulating levels of prolactin in female rats bearing ectopic pituitaries.
    Revista española de fisiología 1988;44(2):205-10.
  • 1988: J J Fernández-Ruiz; A R Bukhari; R Martínez-Arrieta; J A Tresguerres; J A Ramos
    Effects of estrogens and progesterone on the catecholaminergic activity of the adrenal medulla in female rats.
    Life sciences 1988;42(9):1019-28.
  • 1987: A I Esquifino; J J Fernández-Ruiz; M Cebeira; C Agrasal; J A Tresguerres; J A Ramos
    Effect of experimentally induced hyperprolactinemia on growth hormone secretion.
    Revista española de fisiología 1987;43(4):463-8.
  • 1987: A I Esquifino; C Agrasal; R Steger; J J Fernández-Ruiz; J A Ramos; M Cebeira; A Bartke
    Catecholaminergic control of plasma growth hormone and thyrotropin levels in hypophysectomized rats bearing ectopic pituitary transplants.
    Life sciences 1987;41(8):1043-50.
  • 1987: J J Fernández-Ruiz; M Cebeira; C Agrasal; J A Tresguerres; A Bartke; A I Esquifino; J A Ramos
    Possible role of dopamine and noradrenaline in the regulation of prolactin secretion from an ectopic anterior pituitary gland in female rats.
    The Journal of endocrinology 1987;113(1):45-9.
  • 1987: J Fernandez-Ruiz; M Cebeira; C Agrasal; J A Tresguerres; A I Esquifino; J A Ramos
    Effect of elevated prolactin levels on the synthesis and release of catecholamines from the adrenal medulla in female rats.
    Neuroendocrinology 1987;45(3):208-11.
  • 1987: J J Fernández-Ruiz; E Ubeda; M Cebeira; C Agrasal; J A Tresguerres; J A Ramos; A I Esquifino
    Modifications of plasma prolactin levels and catecholamine content in an ectopic anterior pituitary gland transplanted under the kidney capsule.
    Hormone research 1987;25(2):105-12.
  • 1987: J A Ramos; J R Pais; M Cebeira; J Fernandez-Ruiz
    Role of estrogens on striatal dopaminergic activity.
    Journal of steroid biochemistry 1987;27(4-6):683-9.
Register to see more